Indication
Heterozygous Familial Hypercholesterolemia
10 clinical trials
13 products
Product
InclisiranClinical trial
An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-CStatus: Completed, Estimated PCD: 2023-02-13
Clinical trial
Open-label, Phase 1b, Single-ascending Dose and Optional re Dosing Study to Evaluate the Safety of VERVE-101 Administered to Patients With Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Uncontrolled HypercholesterolemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Product
VERVE-101Clinical trial
Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Heterozygous FH Patients on Stable Lipid-Lowering Therapy Requiring Additional LDL-C ReductionStatus: Completed, Estimated PCD: 2023-07-30
Product
lerodalcibepProduct
VERVE-102Clinical trial
Open-label, Phase 1b, Single Ascending Dose Study to Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia or Premature Coronary Artery Disease Who Require Additional Lowering of Low-density Lipoprotein CholesterolStatus: Not yet recruiting, Estimated PCD: 2026-08-01
Product
IBI306Clinical trial
A Study to Evaluate Safety and Efficacy of IBI306 in Patients With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2021-06-30
Product
placeboProduct
PlaceboClinical trial
A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-CStatus: Completed, Estimated PCD: 2022-04-18
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of AK102 in Patients With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2022-09-26
Product
Statins and/or EzetimibeProduct
AK102Clinical trial
Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFHStatus: Completed, Estimated PCD: 2019-11-25
Product
EvolocumabClinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Recombinant Humanized Anti-PCSK9 Monoclonal Antibody Injection in Subjects With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2023-05-08
Product
OngericimabClinical trial
A Phase III, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Atorvastatin Calcium MonotherapyStatus: Completed, Estimated PCD: 2016-12-22
Product
EZ 10 mg + Atorva 20 mgProduct
EZ 10 mg/Atorva 10 mg FDC